knowledge -WSS

knowledge

author：leisure time 2025-09-14 21:38:18 - browse：99

Adobe

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal is expected to net Akili’s shareholders $34 million.

Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued the company at about $1 billion. But despite several strategic pivots, including shifting to direct-to-consumer sales, the company failed to build a sustainable business model. Akili in April announced it would wind down its existing commercial operations and focus on a licensing deal with Japanese pharma company Shionogi while it figured out the best path forward.

Akili is just one of many health tech companies that are struggling following an explosion of investor interest in digital health during the Covid-19 pandemic. In the last month alone, Better Therapeutics, another company making digital treatments, sold its assets for an undisclosed amount after failing to build a business around its app for type 2 diabetes, and Cue Health, a diagnostics startup, shut down after funding interest in its Covid-19 tests evaporated.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： The haunting brain science of long Covid

WSS

Prior authorization will have to move faster under new Biden rule

My yearlong odyssey to get my son’s ADHD medication covered

Medicare Advantage today, explained in one chart

Readout Newsletter: Merck, J&J, and long Covid

How digital therapeutics firms are pivoting after Pear's bankruptcy

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

explore

Dobbs anniversary: the lost opportunity of abortion as health care

Research misconduct: Proposed new rules face resistance

Tori Bowie and the unacceptable rates of Black maternal death

Francis Collins on trust in science and how Covid communications failed

How to save PrEP access — and even expand it

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

How to save PrEP access — and even expand it

What it's like to live with paralysis for one psychologist

How one medical school became remarkably diverse

STAT Report: Patient voices and perspectives

explore

New brain studies show LSD's effects on the brain in full color

Eli Lilly, Pfizer, and others want in on the online prescription market

My yearlong odyssey to get my son’s ADHD medication covered

eGenesis tests gene

A new crop of companies is reshaping the health data economy

Why doctors need education on FDA device approval process

hotspot

hotspot

hotspot

focus